Loading...
Diffusion Pharmaceuticals Inc.
DFFN•NASDAQ
HealthcareBiotechnology
$4.40
$0.41(10.28%)
Diffusion Pharmaceuticals Inc. (DFFN) Stock Overview
Explore Diffusion Pharmaceuticals Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for DFFNStats details for DFFN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for DFFNAnalyst Recommendations details for DFFN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
CEO
Dr. Robert J. Cobuzzi Jr., Ph.D.
Employees
13
Headquarters
300 East Main Street, Charlottesville, VA
Founded
2008